Search
close
search search Search
lang-sel-icon English
mob-search

Blog: Biosimilars Law Blog | 23 June 2015

FDA Updates U.S. Biosimilar Guidances

Five years after enactment of the BPCIA and following its first biosimilar approval, the U.S. Food and Drug Administration finalized its initial guidances describing the scientific and regulatory expectations for biosimilar approval under the 351(k) pathway.

  • Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009. Final 4/28/15.
  • Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009. Draft 5/12/15.
A list of current versions of all biosimilars guidances is readily accessible on FDA’s web site.

Back to main blog

Related blog posts

Biosimilar switching: Dutch MoH announces the set-up of a national system for biological medicinal products

25 May 2016

The Dutch Minister of Health (MoH) announced the set-up of a national system to trace the safety of biological medicinal products. The MoH expects an increase in the number of biosimilar...

FDA Guidance on Transition Biological Products: Implications for Exclusivity and Patent Listings

16 March 2016

FDA issued a draft guidance on March 14, 2016 explaining how the agency proposes to implement the provisions under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) for...

FDA Announces Policy for Unique Nonproprietary Names for Biologics and Biosimilars

31 August 2015

In a Federal Register notice, FDA announced its draft guidance, “Nonproprietary Naming of Biological Products,” in which the agency articulates the need “for biological products licensed...

Article tags

351k pathway Biologics Price Competition and Innovation Act biosimilarity FDA Biosimilars Guidances
Loading data